International Journal of Advanced Research in Biological Sciences
ISSN: 2348-8069
www.ijarbs.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijarbs Coden: IJARQG (USA) Volume 13, Issue 7 - 2026

Review Article

DOI: http://dx.doi.org/10.22192/ijarbs.2026.13.07.003

Innovations in Medical Microbiology and Therapeutic Development: A Comprehensive Review

Venkatajothi Ramarao[1*], Seethalakshmi Illanchezian[2]

[1]*Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

[2] Life Teck Research Centre, Arumbakkam, Chennai, Tamil Nadu, India.

[1]***Correspondence author:** Dr. Venkatajothi Ramarao

Address for correspondence: Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

Email id: *drrvjothi10@gmail.com*

Abstract

Medical microbiology has evolved remarkably over the past few decades, shifting from simple culture-based diagnostics to sophisticated molecular, computational, and nanotechnology-driven approaches. What once felt like a slow and reactive field has gradually become one of the most dynamic frontiers in biomedical science. Infectious diseases caused by bacteria, fungi, viruses, and parasites continue to impose an enormous burden on global health, particularly in low- and middle-income countries where diagnostic and therapeutic resources remain limited. At the same time, the rise of antimicrobial resistance has made even common infections difficult to treat, pushing researchers toward alternative strategies rooted in natural products, peptide-based medicines, and computational drug discovery. Medicinal plants have long served as a foundation for traditional healing, and modern science is now validating many of these remedies through rigorous phytochemical and biological screening. Cancer, too, intersects deeply with microbiology, especially through viral oncogenesis and microbiome dysregulation. This review brings together current evidence across these interconnected domains, exploring innovations in diagnostics, antimicrobial therapy, plant-based drug development, in silico strategies, and nanotechnology. The goal is not simply to summarize what is known, but to trace how these fields are quietly converging toward more integrated and effective solutions for human disease.

Keywords: Antimicrobial resistance, phytochemicals, computational drug discovery, infectious diseases.

1. Introduction

Medicine has always been shaped by our understanding of the microscopic world. From the earliest observations of bacteria under primitive lenses to today's genome-wide sequencing platforms, the field of medical microbiology has never stopped reinventing itself. And yet, despite extraordinary progress, infectious diseases remain stubbornly present in human populations across every continent. Bacterial infections, fungal outbreaks, viral epidemics, and parasitic diseases continue to claim millions of lives each year, often disproportionately affecting children and immunocompromised individuals [1, 2].

The clinical landscape has grown considerably more complex in recent years. Pathogens are evolving faster than many of our therapeutic options, and the pipeline for genuinely new antibiotics has remained frustratingly thin for decades. Antimicrobial resistance, once considered a distant threat, has quietly become one of the most pressing public health emergencies of our time [3, 4]. Organisms like *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Staphylococcus aureus* have developed sophisticated resistance mechanisms that render multiple drug classes ineffective, leaving clinicians with few reliable options [5, 28].Against this backdrop, researchers have increasingly turned to nature for answers. Medicinal plants, which have supported healing traditions across cultures for thousands of years, are now being studied with renewed scientific rigor. Compounds isolated from plants like *Boerhaavia diffusa*, *Euphorbia hirta*, *Achyranthes aspera*, and *Ficus carica* have demonstrated meaningful antioxidant, antibacterial, antifungal, and anticancer activities in laboratory settings [6, 7]. These findings are not merely academic curiosities. They point toward a genuinely rich reservoir of bioactive molecules waiting to be developed into therapeutic agents.

Computational biology has added another dimension to this search. In silico techniques such as molecular docking, peptide design, and protein-ligand interaction modeling allow researchers to screen thousands of candidate molecules in a fraction of the time required for traditional wet-lab approaches [8, 9]. This has opened up exciting possibilities for drug repurposing, where existing approved medications are evaluated against new molecular targets, sometimes with surprisingly promising results [10]. The intersection of computation and biology is no longer speculative. It is producing real candidate molecules with measurable biological relevance.

Nanotechnology, too, has begun reshaping how we think about drug delivery and environmental remediation. Silver nanoparticles biosynthesized from plant extracts, for instance, have shown potent antimicrobial and antifungal activities, offering a more targeted and potentially less toxic alternative to conventional agents [11, 12]. Meanwhile, the relationship between viral infections and cancer development, particularly through oncogenic viruses like human papillomavirus, has made it clear that microbiology and oncology are more intertwined than ever before [13, 24].This review explores these converging innovations across medical microbiology and therapeutic development. It traces the epidemiology of common infections, examines antimicrobial resistance mechanisms, surveys phytochemical discoveries, highlights computational drug design strategies, and considers the role of nanotechnology and cancer biology in shaping the next generation of treatments. Together, these threads tell a coherent story about where the field has been, where it stands today, and where it seems to be heading.

2. Microbial Infections and Epidemiology

Understanding the burden of infectious disease requires looking closely at the populations most affected. Children, particularly school-going children in developing regions, have consistently emerged as one of the most vulnerable groups in epidemiological studies. Intestinal parasitic infections, fungal diseases of the scalp, and oral microbial conditions are remarkably common in

these settings, yet they often go undiagnosed and untreated for long periods [1, 15]. The consequences reach well beyond physical health, affecting school attendance, cognitive development, and overall quality of life in ways that are difficult to fully quantify.

Intestinal helminthic infections, caused by roundworms, hookworms, and tapeworms, remain endemic across tropical and subtropical regions. Studies conducted among school children have reported prevalence rates ranging from 20% to over 60% in highly endemic areas, depending on sanitation levels and access to clean water [13, 16]. Protozoan infections tell a similar story. *Giardia lamblia*, *Entamoeba histolytica*, and *Cryptosporidium* species are frequently identified in stool surveys among pediatric populations, often coexisting with helminthic parasites and compounding the nutritional consequences [1, 17]. What makes these findings particularly striking is how persistently they recur across different geographic settings, suggesting that the problem is systemic rather than isolated.

Fungal infections add another layer to this picture. Tineacapitis, a dermatophytic infection of the scalp, is disproportionately common among school-aged children, particularly in crowded or resource-limited environments. Clinicomycological studies have identified a range of causative dermatophytes, with *Trichophyton* and *Microsporum* species appearing most frequently [11, 18]. Oral thrush caused by *Candida* species has also been documented among children, raising concerns about both immune status and antifungal drug sensitivity patterns [30, 19]. These observations, taken together, paint a picture of overlapping microbial burdens that demand more coordinated public health responses.

Viral infections further complicate the epidemiological landscape, especially when they intersect with immunosuppression. Human papillomavirus infection in women living with HIV has been a particularly well-documented concern, with studies showing significantly elevated rates of high-risk HPV types, including HPV-16, among HIV-positive women compared to the general population [5, 24]. This relationship has profound implications for cervical cancer screening programs, especially in regions where both HIV and HPV are highly prevalent [25, 29]. The co-infection dynamic essentially accelerates oncogenic progression, making early detection not just beneficial but genuinely life-saving.Urinary tract infections and dental caries round out the broader microbial burden picture. Bacterial isolates from urinary tract infections in diverse geographic settings, including parts of South Asia, have revealed patterns of mixed flora with varying antibiotic sensitivity profiles [27, 20]. Similarly, microbiological studies of dental caries have identified a complex community of organisms, including *Streptococcus mutans* and various anaerobes, that contribute to oral disease progression [26, 21](Table 1). These findings reinforce the idea that microbial infections, regardless of their site or causative agent, share common threads of environmental vulnerability, host susceptibility, and diagnostic neglect (Figure 1).

Table 1: Prevalence of Common Microbial Infections across Vulnerable Populations

Infection Type	Causative Agent	Population Affected	Reported Prevalence	Key Risk Factors
Intestinal helminthiasis	*Ascaris*, *Hookworm*, *Trichuris*	School children	20–65%	Poor sanitation, open defecation
Intestinal protozoan infection	*Giardia*, *Entamoeba*, *Cryptosporidium*	School children	15–50%	Contaminated water, poor hygiene
Tineacapitis	*Trichophyton*, *Microsporum* spp.	School children	10–35%	Overcrowding, shared items
Oral candidiasis	*Candida albicans*	Children, immunocompromised	8–25%	Immunosuppression, antibiotic use
HPV infection (high-risk)	HPV-16, HPV-18	HIV-positive women	40–70%	Immunosuppression, multiple partners
Urinary tract infections	*E. coli*, mixed flora	General population	10–30%	Catheter use, poor hygiene
Dental caries microbiome	*S. mutans*, anaerobes	Children, disabled persons	60–80%	Sugar diet, poor oral care

Figure 1: Distribution of Microbial Infection Types among School-Aged Children and Vulnerable Populations



3. Antimicrobial Resistance and Treatment Strategies

Antimicrobial resistance has quietly grown into one of the defining crises of modern medicine. What began as isolated reports of treatment failures has now become a global pattern that threatens to unravel decades of progress in infectious disease management. The World Health Organization has repeatedly flagged resistance as a priority concern, and the clinical evidence supports that urgency [3, 22]. Pathogens that were once reliably treatable with first-line antibiotics are now demanding second and third-line agents, and in some cases, no effective option remains at all.

Pseudomonas aeruginosa offers a particularly instructive example. This gram-negative opportunistic pathogen has demonstrated a remarkable capacity to develop resistance through multiple simultaneous mechanisms, including efflux pump overexpression, outer membrane porin loss, and enzymatic drug inactivation. Studies examining its antibiotic sensitivity patterns, particularly against fluoroquinolones, have revealed worrying trends in clinical isolates from diverse geographic settings [28, 23]. Fluoroquinolones, which were once considered a reliable treatment backbone for *Pseudomonas* infections, are now encountering significant resistance rates that limit their clinical utility in many hospital environments.

Staphylococcus aureus presents a similarly challenging picture. Beyond the well-known problem of methicillin-resistant strains, research has increasingly focused on multidrug export proteins like MepA, which actively pump antimicrobial agents out of bacterial cells before they can exert their effect. Computational studies examining how existing drugs interact with MepA have opened up interesting repurposing possibilities, suggesting that anti-inflammatory agents like tramadol hydrochloride may have previously unrecognized antibacterial potential through efflux pump inhibition [15, 24]. This kind of unexpected cross-disciplinary insight is becoming more common as researchers apply computational tools to resistance biology.

Klebsiella pneumoniae deserves equal attention in any discussion of resistance. Beta-lactamase enzymes, particularly TEM-type beta-lactamases, have made this organism resistant to a broad range of penicillins and cephalosporins, leaving carbapenems as one of the few remaining options in severe infections. The situation is further complicated by the emergence of carbapenem-resistant strains in hospital settings, effectively creating a therapeutic dead end for vulnerable patients [25, 26]. Novel peptide-based approaches targeting beta-lactamase TEM have been proposed as a potential strategy to circumvent this resistance mechanism, with early in silico results showing promising binding interactions [19, 27].

The challenge of resistance is not limited to bacteria alone. Antifungal resistance, particularly among *Candida* species, has become increasingly relevant in clinical practice. Fluconazole, a commonly used antifungal agent, has faced growing resistance among oral *Candida* isolates, especially in populations with prolonged drug exposure or compromised immunity [30, 28]. Studies on oral thrush among school children have highlighted the need for routine sensitivity testing before initiating antifungal therapy, a practice that remains inconsistent in many resource-limited settings. The broader lesson here is that resistance surveillance needs to be integrated into routine clinical care rather than treated as a specialized research activity(Table 2).

Treatment strategies are gradually adapting to this new reality. Drug repurposing has gained considerable momentum as a pragmatic response to the slow pace of new antibiotic development. Rather than investing decades in de novo drug discovery, researchers are systematically evaluating approved drugs against new microbial targets, using computational screening to identify viable candidates quickly and cost-effectively [29, 30]. Alongside this, natural product-based approaches are attracting renewed interest, with plant extracts and biosynthesized nanoparticles demonstrating meaningful antimicrobial activity

against resistant strains in vitro(Figure 2). The convergence of these strategies, computational, natural, and repurposing-based, represents perhaps the most realistic near-term pathway toward managing the resistance crisis.

Table 2: Resistance Patterns of Key Pathogens and Emerging Therapeutic Strategies

Pathogen	Resistance Mechanism	Drugs Affected	Emerging Strategy
Pseudomonas aeruginosa	Efflux pumps, porin loss, enzymatic inactivation	Fluoroquinolones, carbapenems	Peptide-based agents, combination therapy
Staphylococcus aureus	MepA efflux protein, MRSA mechanisms	Methicillin, multiple classes	Drug repurposing, MepA inhibitors
Klebsiella pneumoniae	TEM beta-lactamase, carbapenemase	Penicillins, cephalosporins, carbapenems	Novel peptides, phytochemicals
Candida albicans	Efflux overexpression, target mutation	Fluconazole, azoles	Nanoparticles, plant extracts
Escherichia coli	Extended-spectrum beta-lactamase	Broad-spectrum penicillins	Combination therapy, natural compounds
Mycobacterium tuberculosis	Target mutation, efflux	Isoniazid, rifampicin	Repurposed drugs, host-directed therapy

Figure 2: Overview of Major Antimicrobial Resistance Mechanisms in Clinical Pathogens



4. Phytochemicals and Plant-Based Therapeutics

Plants have served as medicine for as long as human beings have been ill. That relationship, ancient as it is, has never really disappeared. It has simply transformed, moving from folk remedies and traditional healers into university laboratories and pharmaceutical pipelines. What drives this continued interest is not nostalgia but chemistry. Medicinal plants produce an astonishing variety of secondary metabolites, including alkaloids, flavonoids, tannins, terpenoids, and phenolic compounds, many of which have demonstrated real and reproducible biological activity against pathogens, cancer cells, and oxidative stress [39, 40].

Boerhaaviadiffusa, a sprawling herb common across tropical regions, has attracted considerable research attention in recent years. Phytochemical screening of its extracts has revealed a rich profile of bioactive constituents, and in vitro studies have demonstrated significant antioxidant, anti-inflammatory, antibacterial, and anticancer activities [7, 33]. Cytotoxic evaluations against human cancer cell lines have yielded particularly encouraging results, suggesting that compounds within this plant may interfere with cancer cell proliferation through multiple pathways [2, 23]. What makes *B. diffusa* especially interesting is the consistency of these findings across different extract preparations and experimental models, which adds a layer of reproducibility that is not always easy to achieve in natural product research.*Euphorbia hirta* is another plant that has generated meaningful scientific interest. Preliminary phytochemical screening has confirmed the presence of flavonoids, saponins, and tannins, and antibacterial assays have shown activity against a range of clinically relevant organisms [32, 41]. More recently, GC-MS and FT-IR metabolite profiling has allowed researchers to characterize its chemical composition with greater precision, and cytotoxic evaluations on SiHa cervical cancer cells have revealed dose-dependent inhibitory effects that warrant further investigation [14, 42]. The breadth of biological activity observed in *E. hirta* extracts suggests that this plant contains multiple active constituents working synergistically rather than a single dominant compound.

Achyranthes aspera and *Ficus carica* have similarly demonstrated promising profiles in laboratory settings. Methanolic extracts of *A. aspera* have shown both antioxidant activity and cytotoxicity against SiHa cervical cancer cells, pointing toward potential applications in cancer chemoprevention [21, 43]. *Ficus carica* extracts evaluated against MCF-7 human breast cancer cells have shown meaningful growth inhibition, with phytochemical analysis suggesting that phenolic compounds and flavonoids are likely among the primary contributors to this activity [20, 44]. These findings, while still at the in vitro stage, provide a strong rationale for advancing these plants into more rigorous preclinical evaluation. *Ipomoea obscura*, a lesser-studied plant, has also entered the research conversation. Assessment of its crude extracts for antioxidant, anti-inflammatory, antibacterial, and anticancer activities has revealed a surprisingly broad spectrum of biological effects [7, 45]. This kind of multi-activity profile is actually quite characteristic of complex plant extracts, where numerous compounds interact with multiple biological targets simultaneously. It presents both an opportunity and a challenge, since isolating the specific active constituents responsible for each activity requires considerable additional work(Table 3).

Beyond individual plant species, the broader story of phytochemical research is one of methodological maturation. Earlier studies relied heavily on simple disk diffusion assays and colorimetric antioxidant tests. More recent work increasingly incorporates cell-based cytotoxicity models, advanced spectroscopic characterization, and even molecular docking to understand how plant-derived compounds interact with specific protein targets [46, 47]. This evolution in methodology is gradually closing the gap between traditional knowledge and evidence-based medicine, building a more credible scientific foundation for plant-based therapeutic development.

Table 3: Bioactive Medicinal Plants, Their Phytochemical Constituents, and Reported Biological Activities

Plant Species	Major Phytochemicals	Biological Activities	Experimental Model
Boerhaavia diffusa	Alkaloids, flavonoids, phenolics	Antioxidant, anticancer, anti-inflammatory, antibacterial	In vitro cell lines, extract assays
Euphorbia hirta	Flavonoids, saponins, tannins	Antibacterial, anticancer, antioxidant	SiHa cells, disk diffusion
Achyranthes aspera	Phenolics, alkaloids, saponins	Antioxidant, cytotoxic	SiHa cervical cancer cells
Ficus carica	Phenolics, flavonoids, terpenoids	Anticancer, antioxidant	MCF-7 breast cancer cells
Ipomoea obscura	Flavonoids, tannins, alkaloids	Antioxidant, anti-inflammatory, antibacterial, anticancer	In vitro extract assays
Tephrosia purpurea	Flavonoids, rotenoids, phenolics	Antibacterial against spoilage pathogens	Disk diffusion, MIC assays
Terminalia chebula	Tannins, gallic acid, ellagic acid	Antioxidant, antifungal	Silver nanoparticle synthesis

5. Computational Approaches in Drug Discovery

The way we discover drugs has changed profoundly. For much of the twentieth century, drug discovery was essentially a process of trial and error, screening thousands of compounds in the hope that something would show biological activity worth pursuing. That approach was expensive, time-consuming, and often disappointing. Computational methods have fundamentally altered this equation, allowing researchers to model molecular interactions, predict binding affinities, and design novel therapeutic candidates entirely in silico before a single experiment is run in a laboratory [50, 51].

Molecular docking is perhaps the most widely used computational tool in this space. By simulating how a small molecule or peptide fits into the active site of a target protein, docking studies can rapidly identify candidates with favorable binding geometry and energy profiles. This has proven particularly valuable in the context of antimicrobial and anticancer drug discovery, where target proteins are well characterized and structural data is increasingly available [52, 53]. Studies targeting *Anopheles gambiae* proteins using novel peptides derived through in silico approaches have demonstrated how computational screening can accelerate the identification of vector-control candidates that would otherwise require years of conventional screening [9, 54].

Peptide-based drug design represents one of the most exciting frontiers in computational therapeutics. Unlike small molecule drugs, peptides can be designed to interact with protein surfaces in highly specific ways, making them attractive candidates against targets that have traditionally been considered undruggable. In silico strategies have been used to design novel peptides derived from *Boerhaavia diffusa* that target transmembrane proteins involved in cervical cancer progression, with docking results suggesting strong and selective binding interactions [3, 55]. Similar approaches have been applied to mosquito-borne disease vectors, with peptides designed to target *Culex quinquefasciatus* proteins showing favorable computational profiles that support further experimental validation [18, 56]. Drug repurposing through computational screening has also gained considerable momentum. The

rationale is straightforward. Approved drugs have already cleared safety and pharmacokinetic hurdles, so identifying new indications for them is far more efficient than developing entirely new chemical entities. Computational evaluation of linezolid and ciprofloxacin against mutant ESR1 protein in breast cancer represents a compelling example of this strategy, with in silico results suggesting that these antibiotics may have previously unrecognized anticancer potential through estrogen receptor interactions [8, 57]. Similarly, the computational evaluation of tramadol hydrochloride against MepA in *Staphylococcus aureus* has revealed unexpected antibacterial repurposing possibilities that deserve wet-lab confirmation [15, 58].

The broader workflow of in silico drug discovery typically involves several sequential steps, beginning with target identification and structure retrieval, followed by ligand preparation, molecular docking, and binding energy calculation. More advanced studies incorporate molecular dynamics simulations to assess the stability of protein-ligand complexes over time, and ADMET prediction tools to evaluate the pharmacokinetic properties of candidate molecules [59, 60]. This systematic approach has dramatically improved the hit rate of compounds advancing to experimental validation, making computational screening an indispensable component of modern drug discovery programs.

What is perhaps most encouraging about the computational turn in drug discovery is its democratizing effect. Research groups in lower-resource settings, which might lack access to expensive high-throughput screening facilities, can now contribute meaningfully to global drug discovery efforts using freely available bioinformatics tools and public protein databases(Figure 3). This has broadened the geographic and institutional diversity of drug discovery research in ways that are genuinely good for the field and, ultimately, for patients.

Figure 3: General Workflow of In Silico Drug Discovery Applied in Reviewed Studies



6. Cancer Biology and Anticancer Development

Cancer and microbiology share a relationship that is older and deeper than many people realize. Long before the molecular mechanisms were understood, clinicians had noticed that certain infections seemed to increase cancer risk in ways that went beyond simple inflammation. Today, we know that several viruses, bacteria, and even parasites can directly contribute to malignant transformation, making the oncology-microbiology interface one of the most clinically important areas in biomedical research [62, 63].

Human papillomavirus stands at the center of this conversation. HPV, particularly high-risk types 16 and 18, is now firmly established as the primary etiological agent of cervical cancer, responsible for the vast majority of cases worldwide. Studies examining HPV prevalence in HIV-positive women have consistently shown that immunosuppression dramatically accelerates HPV persistence and oncogenic progression [5, 24]. The co-infection dynamic creates a compounding risk that standard cervical screening programs are not always equipped to address, particularly in high-burden settings where both infections are prevalent and healthcare infrastructure is stretched [25, 29].

Understanding this relationship more deeply has direct implications for vaccination strategy, screening frequency, and treatment prioritization.The anticancer potential of medicinal plants has emerged as a genuinely productive research direction. In vitro cytotoxicity studies using human cancer cell lines have become a standard first step in evaluating plant-derived compounds, and the results have been encouraging across multiple species and cancer types. *Boerhaavia diffusa* extracts have shown cytotoxic activity against several cancer cell lines, with mechanisms likely involving apoptosis induction and cell cycle disruption [2, 23]. *Ficus carica* extracts evaluated against MCF-7 breast cancer cells have demonstrated meaningful growth inhibition, while *Achyranthes aspera* and *Euphorbia hirta* have shown activity against SiHa cervical cancer cells [20, 21, 14]. Taken together, these findings suggest a rich pool of plant-derived anticancer leads waiting for more systematic investigation.

Computational approaches have added new depth to anticancer drug discovery. Molecular docking studies targeting cancer-specific proteins have identified several promising candidates, including peptides derived from medicinal plants and repurposed pharmaceutical agents. The computational evaluation of linezolid and ciprofloxacin against mutant ESR1 in breast cancer is a particularly interesting example, because it suggests that drugs developed for entirely different indications may have meaningful anticancer activity through mechanisms that would not have been predicted without in silico screening [8, 64]. This kind of cross-domain discovery is one of the most exciting possibilities that computational biology has opened up for cancer research.

Nanoparticle-based approaches are also making inroads in anticancer development. Silver nanoparticles biosynthesized from plant extracts like *Terminalia chebula* have shown not only antimicrobial but also potential anticancer activity in preliminary studies, raising interesting questions about whether their biological effects extend beyond simple membrane disruption [12, 65]. The surface properties of nanoparticles can be tuned to enhance selective uptake by cancer cells, and plant-derived synthesis methods offer a more environmentally friendly alternative to chemically synthesized nanoparticles [66, 67]. While this work remains largely at the proof-of-concept stage, the trajectory is genuinely promising.

Orthostatic hypotension and mental health considerations in aging populations represent an often-overlooked dimension of cancer care and chronic disease management more broadly. Studies examining the impact of aging on orthostatic hypotension have highlighted how physiological vulnerabilities in older adults can complicate treatment decisions and increase

adverse event risks in both infectious disease and oncology contexts [6, 68]. This reminder that patients exist within complex physiological and social contexts is an important corrective to overly reductionist approaches to drug development and clinical management.

7. Nanotechnology and Environmental Applications

Nanotechnology has entered medical microbiology through multiple doors simultaneously, and its impact is being felt across diagnostics, therapeutics, and environmental health. The ability to engineer materials at the nanoscale has created entirely new possibilities for drug delivery, pathogen detection, and environmental remediation that simply did not exist a generation ago [4, 69]. What makes nanotechnology particularly compelling in the biomedical context is the way it bridges disciplines, bringing together chemistry, physics, biology, and engineering in ways that produce genuinely novel solutions.

Biosynthesized nanoparticles, particularly silver nanoparticles produced using plant extracts, have attracted enormous research interest for their antimicrobial properties. The synthesis of silver nanoparticles using *Terminalia chebula* extracts has been shown to produce particles with potent antioxidant and antifungal activities, with the plant phytochemicals serving both as reducing agents and as stabilizing caps that influence particle size and surface reactivity [12, 70]. These green synthesis approaches are appealing not only because they avoid hazardous chemical reagents but also because the phytochemical capping agents may themselves contribute to biological activity, creating a synergistic effect between the nanoparticle core and its organic coating.

The antimicrobial mechanisms of silver nanoparticles are multifaceted and are thought to involve disruption of bacterial cell membranes, interference with respiratory chain enzymes, and generation of reactive oxygen species that damage cellular components [71, 72]. This multi-target mechanism is particularly valuable in the context of antimicrobial resistance, because it is considerably harder for bacteria to develop resistance against multiple simultaneous attack modes than against a single molecular target. Studies have demonstrated activity against both gram-positive and gram-negative organisms, as well as against fungal pathogens like *Candida* species, broadening the potential therapeutic applications considerably [12, 73].

Beyond direct antimicrobial applications, nanotechnology is finding important roles in environmental pollution management. The intersection of nanomaterials and environmental science has generated growing interest in using engineered nanoparticles for the detection and remediation of environmental contaminants, including heavy metals, pesticides, and microbial pollutants in water and soil [4, 74]. Advanced nanotechnology-based sensors can detect contaminants at concentrations far below what conventional analytical methods can reliably measure, with obvious implications for public health monitoring in areas where environmental contamination drives disease burden.

Biotechnological applications of microbial and enzymatic processes are also contributing to this space. The production of oleic acid from mango kernel waste using probiotic bacteria isolated from marine fish represents an innovative intersection of microbiology, waste valorization, and industrial biotechnology [10, 75]. This kind of circular bioeconomy approach, where biological processes transform agricultural waste into valuable biochemical products, reflects a broader shift in how researchers think about the productive potential of microbial communities. The marine environment in particular has proven to be a rich source of organisms with unusual enzymatic capabilities that are difficult to find in terrestrial microbiomes.

The regulatory and safety dimensions of nanotechnology in medicine deserve honest acknowledgment. Despite the promise, concerns about nanoparticle toxicity, long-term bioaccumulation, and environmental persistence

remain active areas of investigation [76 - 80]. Responsible development of nanomedicine requires parallel investment in safety assessment, and the field has learned some hard lessons from earlier enthusiasm that outpaced rigorous toxicological evaluation. Nevertheless, the overall trajectory of nanotechnology in medical microbiology remains strongly positive, with each year bringing more refined synthesis methods, better characterized particles, and more targeted delivery systems.

8. Parasitology and Vector-Borne Disease Management

Parasitic diseases occupy a special place in the landscape of global infectious disease [81- 84]. They tend to affect the world's most economically vulnerable populations, they are chronically underfunded in research terms relative to their disease burden, and they present unique therapeutic challenges because the parasites involved are eukaryotic organisms whose biology overlaps significantly with that of their human hosts [85-89]. This biological proximity makes selective toxicity genuinely difficult to achieve and has historically limited the therapeutic options available for many parasitic infections.

Intestinal parasites remain a major public health challenge across tropical and subtropical regions. Helminthic infections caused by soil-transmitted helminths continue to affect hundreds of millions of children globally, impairing physical growth, cognitive development, and school performance in ways that have lasting socioeconomic consequences [90- 95]. Protozoan infections caused by organisms like *Giardia* and *Entamoeba* add further complexity, often coexisting with helminthic infections and creating compounding nutritional deficits that mass drug administration programs struggle to fully address [96-100]. The epidemiological evidence consistently points to the need for integrated control approaches that combine pharmacological treatment with improvements in water, sanitation, and hygiene infrastructure.

African trypanosomiasis represents one of the most clinically complex parasitic diseases encountered in sub-Saharan Africa [101-105]. Human African trypanosomiasis caused by *Trypanosoma bruceirhodesiense* progresses through two distinct stages, with stage two involving central nervous system invasion that dramatically increases both disease severity and treatment complexity. Studies examining seizure prevalence in stage-two rhodesiense trypanosomiasis have highlighted the neurological burden of this disease and the significant challenges it poses for clinical management in resource-limited settings [106-110]. The association between seizures and disease stage underscores the need for earlier diagnosis and treatment initiation before central nervous system involvement becomes established.

Vector control represents one of the most promising avenues for reducing the burden of parasitic and vector-borne diseases [111-113]. Mosquito-borne infections including malaria, dengue, filariasis, and Zika virus disease collectively affect billions of people globally, and the limitations of existing vector control tools, including insecticide resistance and environmental concerns, have created genuine urgency around the development of new approaches [114-116]. Computational strategies for designing novel peptides targeting *Anopheles gambiae* and *Culex quinquefasciatus* represent an innovative contribution to this effort, offering the possibility of highly specific vector-control agents that minimize collateral effects on non-target organisms [117-119]. These in silico approaches are still in early stages but represent exactly the kind of creative thinking that the field needs.

The broader management of vector-borne diseases requires coordinated action across multiple levels, from individual patient care to community-level vector control to international surveillance and response systems. Drug resistance in malaria parasites, insecticide resistance in mosquito vectors, and the emergence of new vector-borne pathogens all demand adaptive management strategies that can respond quickly to changing conditions [120]. Research innovations in peptide

design, computational biology, and plant-based medicine all have roles to play in building a more resilient toolkit for parasitic disease management, even if the path from laboratory discovery to clinical application remains long and uncertain.

9. Conclusion and Future Perspectives

Looking across the breadth of innovations reviewed here, what emerges most clearly is not any single breakthrough but rather a pattern of convergence. Fields that once operated largely in isolation, microbiology, pharmacognosy, computational biology, nanotechnology, and oncology, are increasingly drawing on each other's tools, insights, and methodologies. This convergence is not accidental. It reflects a growing recognition that the problems we face in infectious disease, antimicrobial resistance, and cancer are too complex to be solved from within any single disciplinary framework.

The epidemiological evidence reviewed here makes clear that infectious diseases, particularly among vulnerable populations like children and immunocompromised individuals, remain a pressing global health priority. Intestinal parasites, fungal infections, viral diseases, and bacterial infections continue to impose enormous burdens that are unevenly distributed across geographic and socioeconomic lines. Addressing these burdens requires not only better drugs but also stronger health systems, improved diagnostics, and the kind of sustained political commitment that scientific innovation alone cannot substitute for.

Phytochemical research has matured considerably and now offers a credible pipeline of plant-derived candidates with demonstrated in vitro activity against relevant biological targets. Plants like *Boerhaavia diffusa*, *Euphorbia hirta*, *Achyranthes aspera*, and *Ficus carica* have moved from traditional use into rigorous scientific investigation, with results that justify continued investment in their preclinical development. The challenge now is to bridge the gap between promising in vitro findings and validated in vivo efficacy, which requires systematic investment in animal studies, toxicological profiling, and ultimately clinical evaluation.

Computational drug discovery has demonstrated its value as an accelerator and a democratizer of the drug development process. In silico approaches have identified novel peptide candidates, revealed repurposing possibilities for existing drugs, and generated mechanistic insights into resistance biology that would have been difficult or impossible to obtain through purely experimental means. As structural databases continue to expand and computational tools become more accessible, the contribution of in silico methods to the drug discovery pipeline will only grow. The integration of artificial intelligence and machine learning into these workflows represents perhaps the most transformative near-term development on the horizon.

Nanotechnology continues to evolve as both a therapeutic platform and an environmental tool, with green synthesis approaches offering sustainable pathways to biologically active nanoparticles. The challenge of translating these laboratory-scale achievements into clinically validated and regulatory-approved products remains significant, but the scientific foundation is steadily strengthening. Future work should prioritize rigorous safety assessment alongside efficacy evaluation to ensure that nanotechnology-based interventions meet the standards required for clinical application.Ultimately, the innovations reviewed in this article collectively point toward a more integrated, adaptive, and scientifically sophisticated approach to medical microbiology and therapeutic development. The path forward is neither simple nor straight, but the direction is increasingly clear. By combining the insights of traditional medicine with the precision of computational biology, the creativity of nanotechnology, and the rigor of modern pharmacology, the field is building toward therapeutic solutions that are more effective, more

accessible, and more attuned to the biological complexity of the diseases they aim to treat.

Conflict of interest

The authors disclose no conflicts of interest.

Funding

None.

References

1. World Health Organization. (2023). Global antimicrobial resistance and use surveillance system (GLASS) report. WHO Press.
2. Bloom, D. E., & Cadarette, D. (2019). Infectious disease threats in the twenty-first century: Strengthening the global response. Frontiers in Immunology, 10, 549. https://doi.org/10.3389/fimmu.2019.00549
3. Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 40(4), 277–283.
4. Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., & Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
5. Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Infectious Diseases, 22(9), 1214–1226.
6. Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015). Antimicrobial resistance: A global multifaceted phenomenon. Pathogens and Global Health, 109(7), 309–318. https://doi.org/10.1179/2047773215Y.0000000030
7. Venkatajothi, R. (2017). Clinicomycological study of *Tinea capitis* infections among school children. International Journal of Current Research in Medical Sciences, 3(2), 35–41.
8. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285
9. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z
10. Venkatajothi, R., Selvam, P., & Amudha, C. (2024). In vitro evaluation of antioxidant and antifungal activities of silver nanoparticles biosynthesized *Terminalia chebula*. International Journal of Current Research in Chemistry and Pharmaceutical Sciences, 11(8), 38–47.
11. Cragg, G. M., & Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. Biochimicaet Biophysica Acta, 1830(6), 3670–3695. https://doi.org/10.1016/j.bbagen.2013.02.008
12. Gupta, P. D., &Birdi, T. J. (2017). Development of botanicals to combat antibiotic resistance. Journal of Ayurveda and Integrative Medicine, 8(4), 266–275. https://doi.org/10.1016/j.jaim.2017.01.003
13. Venkatajothi, R., Illanchezian, S., & Amudha, C. (2024). Evaluation of preliminary phytochemical screening and anticancer activities of *Ficus carica* L on MCF-7 human breast cancer cells. International Journal of Advanced Research in Biological Sciences, 11(9), 154–161.
14. Srivastava, J., Lambert, J., & Vietmeyer, N. (1996). Medicinal plants: An expanding role in development. World Bank.
15. Venkatajothi, R., & Illanchezian, S. (2023). Determination of antioxidant activities and anticancer activity of methanol extract of *Achyranthes aspera* in SiHa cells. International Journal of Current Research in Medical Sciences, 9(11), 29–34.
16. Cos, P., Vlietinck, A. J., Berghe, D. V., & Maes, L. (2006). Anti-infective potential of natural products: How to develop a stronger in vitro proof-of-concept. Journal of

Ethnopharmacology, 106(3), 290–302. https://doi.org/10.1016/j.jep.2006.04.003

17. Venkatajothi, R., Athiappan, M., Mwanakasale, V., Subramanian, B., Balapala, K. R., & Amudha, C. (2025). Phytochemical constituents and assessment of crude extracts from *Ipomoea obscura* for antioxidant, anti-inflammatory, antibacterial and anti-cancer activities. Research Journal of Pharmacy and Technology, 18(5), 2297–2304. https://doi.org/10.52711/0974-360X.2025.00329
18. Lipinski, C. A., & Hopkins, A. (2004). Navigating chemical space for biology and medicine. Nature, 432(7019), 855–861. https://doi.org/10.1038/nature03193
19. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
20. Venkatajothi, R., & Vijayalakshmi, K. (2026). Phytochemical screening, in vitro antioxidant assay, GC-MS, FT-IR metabolite profiling, and cytotoxic evaluation of Euphorbia hirta L on SiHa cervical cancer cells. Journal of Community Health Research, 16(2), 38–50.
21. Trott, O., & Olson, A. J. (2010). AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
22. Venkatajothi, R., Sudhalakshmi, Y., Athiappan, M., Kandasamy, V., & Yavanika, V. (2025). Impact of the anti-inflammatory medication tramadol hydrochloride on Staphylococcus aureus multidrug export protein, MepA, using in silico chemical repurposing methods. Journal of Zoological Investigations, 11(1), 610–619. https://doi.org/10.33745/ijzi.2025.v11i01.064
23. Irwin, J. J., & Shoichet, B. K. (2005). ZINC: A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 177–182. https://doi.org/10.1021/ci049714
24. Venkatajothi, R., & Illanchezian, S. (2023). In vitro cytotoxic analysis of *Boerhaavia diffusa* Linn. International Journal of Advanced Research in Biological Sciences, 10(2), 202–208.
25. Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature, 432(7019), 862–865. https://doi.org/10.1038/nature03197
26. Venkatajothi, R., & Munivelan, B. (2025). 3D peptide–protein docking between a novel peptide derived from *Boerhavia diffusa* and a cervical cancer protein, transmembrane protein 50A (TM50A), using in silico strategies. International Journal of Applied Research, 11(2), 293–298. https://doi.org/10.22271/allresearch.2025.v11.i2d.12376
27. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
28. Venkatajothi, R., Vinod Kumar, C. S., & Illanchezian, S. (2023). Human papillomavirus type 16 in HIV women. International Journal of Current Research in Medical Sciences, 9(6), 1–6.
29. zurHausen, H. (2009). Papillomaviruses in the causation of human cancers: A brief historical account. Virology, 384(2), 260–265. https://doi.org/10.1016/j.virol.2008.11.046
30. Venkatajothi, R., & Vinod Kumar, C. S. (2010). Prevalence of human papilloma virus type 16 in AIDS women. Biomedicine, 30(2), 134–138.
31. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007). Human papillomavirus and cervical cancer. The Lancet, 370(9590), 890–907. https://doi.org/10.1016/S0140-6736(07)61416-0

32. Venkatajothi, R., Vinod Kumar, C. S., &Rajendran, P. (2011). Screening of high risk human papilloma virus type 16 in AIDS women. Biomedicine, 31(3), 302–306.
33. De Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., & zurHausen, H. (2004). Classification of papillomaviruses. Virology, 324(1), 17–27. https://doi.org/10.1016/j.virol.2004.03.033
34. Venkatajothi, R. (2026). Computational evaluation of linezolid and ciprofloxacin targeting mutant ESR1 protein in breast cancer. Research Journal of Biotechnology, 21(7), 205–210. https://doi.org/10.25303/217rjbt2050210
35. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708
36. Venkatajothi, R., & Illanchezian, S. (2023). Studies on preliminary phytochemical screening and in vitro antibacterial activities of Euphorbia hirta. International Journal of Advanced Research, 10(7), 57–62.
37. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
38. Venkatajothi, R., Athiappan, M., Thirunavukkarasu, R., Raja, M. M. M., & Kandasamy, V. (2025). Phytochemical screening, antioxidant, and cytotoxicity studies of Boerhaviadiffusa. Journal of Biosciences, 26(4), 144–152.
39. Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., & Kroemer, G. (2018). Molecular mechanisms of cell death: Recommendations of the nomenclature committee on cell death 2018. Cell Death and Differentiation, 25(3), 486–541. https://doi.org/10.1038/s41418-017-0012-4
40. Subramanian, K., Santhosh Kumar, A. W., Rajesh, R. P., & Venkatajothi, R. (2024). Nanomaterials in environment pollution and sustainable advanced technologies. Environmental Science and Pollution Research, 31, 67315–67316. https://doi.org/10.1007/s11356-024-35372-6
41. Pelgrift, R. Y., & Friedman, A. J. (2013). Nanotechnology as a therapeutic tool to combat microbial resistance. Advanced Drug Delivery Reviews, 65(13–14), 1803–1815. https://doi.org/10.1016/j.addr.2013.07.011
42. Venkatajothi, R., Natarajan, K., Mary, R. A., Venkatesan, S., Subramanian, B., & Yokesh, V. (2026). Discovery of novel peptides targeting *Anopheles gambiae* using in silico approaches. International Journal of Drug Delivery Technology, 16(3), 132–139. https://doi.org/10.25258/ijddt.16.3.17
43. Anandan, R., Kannan, V., Sivakumar, L., Venkatajothi, R., &Athiappan, M. (2024). Production of oleic acid from mango kernels waste using probiotic bacteria isolated from marine fishes. Asian Journal of Chemistry, 36(7), 1511–1517. https://doi.org/10.14233/ajchem.2024.31515
44. Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. Biotechnology Advances, 27(1), 76–83. https://doi.org/10.1016/j.biotechadv.2008.09.002
45. Venkatajothi, R., Selvam, P., & Selvam, M. B. (2025). Identification of a novel peptide-based medicine against *Aedes aegypti* using in silico techniques. Indian Journal of Mosquito Research, 12(3), 27–31. https://doi.org/10.22271/23487941.2025.v12.i3a.837
46. Singh, R., &Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004
47. Venkatajothi, R., Raja, M. M. M., & Kandasamy, V. (2025). Discovery of a de novo medicine derived from peptide against *Culex quinquefasciatus* using computational protocols. Indian Journal of Mosquito Research, 12(3), 32–36. https://doi.org/10.22271/23487941.2025.v12.i3a.838
48. Kuppusamy, P., Yusoff, M. M., Maniam, G. P., &Govindan, N. (2016). Biosynthesis of metallic nanoparticles using plant derivatives and their new avenues in pharmacological

applications: An updated report. Saudi Pharmaceutical Journal, 24(4), 473–484. https://doi.org/10.1016/j.jsps.2014.11.013

49. Venkatajothi, R., Selvam, P., & Selvam, M. B. (2025). Identification of a novel peptide-based medicine derived from *Boerhavia diffusa* against β-lactamase TEM of *Klebsiella pneumoniae* using in silico approaches. Uttar Pradesh Journal of Zoology, 46(10), 385–393. https://doi.org/10.56557/upjoz/2025/v46i104997
50. Galdiero, S., Falanga, A., Vitiello, M., Cantisani, M., Marra, V., & Galdiero, M. (2011). Silver nanoparticles as potential antiviral agents. Molecules, 16(10), 8894–8918. https://doi.org/10.3390/molecules16108894
51. Balapala, K. R., Mwanakasale, V., Mukanga, B., Venkatajothi, R., Silitongo, M. S., Sayana, S. B., & Mushabati, F. (2025). Impact of ageing on orthostatic hypotension and mental health: A cross-sectional study. Romanian Medical Journal, 72(1). https://doi.org/10.37897/RMJ.2025.1.7
52. Hajdu, S., Holinka, J., Reichmann, S., Hirschl, A. M., Graninger, W., & Presterl, E. (2010). Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms. Antimicrobial Agents and Chemotherapy, 54(10), 4078–4084. https://doi.org/10.1128/AAC.00275-10
53. Venkatajothi, R. (2017). Prevalence of oral thrush yeasts among school children with special emphasis of fluconazole antifungal drug. International Journal of Current Research in Medical Sciences, 3(3), 125–130.
54. Mwanakasale, V., Venkatajothi, R., & Mwansa, M. (2023). Prevalence and risk factors for seizures in stage-2 of rhodesiense human African trypanosomiasis in Zambia from January 2013 to July 2022. International Journal of Current Innovations in Advanced Research, 5(4), 1–4.
55. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., &Pulcini, C. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318–327. https://doi.org/10.1016/S1473-3099(17)30753-3
56. Vijayalakshmi, K., Raja, M. M. M., Venkatajothi, R., Sivamanikandan, P., Dharsini, P. P., Crossia, A. W. F., Sivaprakasam, S., & Varadharajan, S. (2025). Exploring the antibacterial potential of Tephrosiapurpurea extracts against tomato spoilage pathogens. Journal of Community Health Research, 15(3), 1052–1061.
57. Mancuso, G., Midiri, A., Gerace, E., &Biondo, C. (2021). Bacterial antibiotic resistance: The most critical pathogens. Pathogens, 10(10), 1310. https://doi.org/10.3390/pathogens10101310
58. Venkatajothi, R., Shanthi, J., Jaikumar, S., Arumugam, S., Nivedha, R., Rajendran, S. M., & Rajendran, P. (2002). Isolation and characterization of microbes in dental caries from Salem district. International Journal of Applied Microbiology, 2(1), 57–58.
59. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., &Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42–51. https://doi.org/10.1038/nrmicro3380
60. Venkatajothi, R., Rajendran, P., & Ashok, G. (2006). Study of bacterial isolation from urinary tract infections in southern part of Nepal. International Journal of Applied Microbiology, 6(1), 01–03.
61. Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010). How antibiotics kill bacteria: From targets to networks. Nature Reviews Microbiology, 8(6), 423–435. https://doi.org/10.1038/nrmicro2333
62. Venkatajothi, R., Rajendran, P., Vinod Kumar, C. S., Nivedha, R., & Rajendran, M. (2011). Oral microbial diseases and care for people with mental, physical and social disability. International Journal of Applied Microbiology, 14(1), 1–8.

63. Coates, A. R. M., Halls, G., & Hu, Y. (2011). Novel classes of antibiotics or more of the same? British Journal of Pharmacology, 163(1), 184–194. https://doi.org/10.1111/j.1476-5381.2011.01250.x
64. Venkatajothi, R. (2017). Incidence of intestinal protozoa infections among school going children. International Journal of Current Research in Medical Sciences, 3(4), 54–58.
65. Cox, G., & Wright, G. D. (2013). Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions. International Journal of Medical Microbiology, 303(6–7), 287–292. https://doi.org/10.1016/j.ijmm.2013.02.009
66. Venkatajothi, R., Rajagopal, G., & Vinod Kumar, C. S. (2010). Current antibiotic pattern of *Pseudomonas aeruginosa* with special emphasis on fluoroquinolone group of antibiotics. Biomedicine, 30(4), 515–520.
67. Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., & Daszak, P. (2008). Global trends in emerging infectious diseases. Nature, 451(7181), 990–993. https://doi.org/10.1038/nature06536
68. Venkatajothi, R. (2010). Prevalence of intestinal helminthic infections among school going children. International Journal of Current Research in Biological Medicine, 2(1), 33–38.
69. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., & Bartlett, J. G. (2009). Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases, 48(1), 1–12. https://doi.org/10.1086/595011
70. Venkatajothi, R. (2017). In vitro anti-cancer activity of *Boerhaavia diffusa* Linn. International Journal of Current Research in Biological Medicine, 2(3), 20–24.
71. Daszak, P., Cunningham, A. A., & Hyatt, A. D. (2000). Emerging infectious diseases of wildlife: Threats to biodiversity and human health. Science, 287(5452), 443–449. https://doi.org/10.1126/science.287.5452.443
72. Venkatajothi, R. (2026). A comprehensive review on emerging strategies for disease prevention and therapy: From epidemiology to computational medicine. International Journal of Advanced Multidisciplinary Research, 13(4), 99–115. http://dx.doi.org/10.22192/ijamr.2026.13.04.009
73. Lewis, K. (2013). Platforms for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371–387. https://doi.org/10.1038/nrd3975
74. Venkatajothi, R. (2026). Translational biomedical research: Bridging infectious diseases, cancer biology, phytomedicine, and bioinformatics. An integrated review. International Journal of Advanced Research in Biological Sciences, 13(1), 164–178. http://dx.doi.org/10.22192/ijarbs.2026.13.01.013
75. Kumaran, S., & Balaji, M. (2019). Computational drug discovery approaches: Current status and future prospects. Journal of Biomolecular Structure and Dynamics, 37(8), 2026–2037. https://doi.org/10.1080/07391102.2018.1474638
76. Venkatajothi, R. (2026). A review on bridging traditional medicinal plants and computational therapeutics: New frontiers in biomedical research. International Journal of Advanced Research in Biological Sciences, 13(5), 83–101. http://dx.doi.org/10.22192/ijarbs.2026.13.05.009
77. Liou, G. Y., & Storz, P. (2010). Reactive oxygen species in cancer. Free Radical Research, 44(5), 479–496. https://doi.org/10.3109/10715761003667554
78. Venkatajothi, R. (2026). Interdisciplinary approaches in modern biomedical sciences: Applications in infectious diseases, cancer, and drug discovery. International Journal of Advanced Multidisciplinary Research, 13(5), 94–110. http://dx.doi.org/10.22192/ijamr.2026.13.05.009

79. Woolhouse, M. E. J., & Gowtage-Sequeria, S. (2005). Host range and emerging and reemerging pathogens. Emerging Infectious Diseases, 11(12), 1842–1847. https://doi.org/10.3201/eid1112.050997
80. Venkatajothi, R. (2026). A multidisciplinary review on natural products, peptide therapeutics, and nanomedicine in human health and disease: Current perspectives. International Journal of Current Research in Medical Sciences, 12(6), 37–52. http://dx.doi.org/10.22192/ijcrms.2026.12.06.005
81. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747. https://doi.org/10.1128/CMR.00102-15
82. Venkatajothi, R. (2026). Recent advances in infectious diseases, natural product therapeutics, nanotechnology, and computational drug discovery: A review. International Journal of Current Research in Chemistry and Pharmaceutical Sciences. http://dx.doi.org/10.22192/ijcrcps.2026.13.06.003
83. Bhutani, M., Bhutani, J., & Bahl, A. (2013). Ethnopharmacological approaches to drug discovery. Recent Patents on Drug Delivery and Formulation, 7(3), 189–196. https://doi.org/10.2174/1872211311307030003
84. Venkatajothi, R., & Vinod Kumar, C. S. (2011). Human papilloma virus infection in women with the human immunodeficiency virus type-1. International Journal of Biological and Medical Research, 2(3), 771–774.
85. Hotez, P. J., Brindley, P. J., Bethony, J. M., King, C. H., Pearce, E. J., & Jacobson, J. (2008). Helminth infections: The great neglected tropical diseases. Journal of Clinical Investigation, 118(4), 1311–1321. https://doi.org/10.1172/JCI34261
86. Petersen, E., Petersen, E., & Koopmans, M. (2020). Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *The Lancet Infectious Diseases*, 20(9), e238–e244. https://doi.org/10.1016/S147.
87. Patz, J. A., Daszak, P., Tabor, G. M., Aguirre, A. A., Pearl, M., Epstein, J., & Bradley, D. J. (2004). Unhealthy landscapes: Policy recommendations on land use change and infectious disease emergence. Environmental Health Perspectives, 112(10), 1092–1098. https://doi.org/10.1289/ehp.6877
88. Bethony, J., Brooker, S., Albonico, M., Geiger, S. M., Loukas, A., Diemert, D., &Hotez, P. J. (2006). Soil-transmitted helminth infections: *Ascariasis, trichuriasis,* and hookworm. The Lancet, 367(9521), 1521–1532. https://doi.org/10.1016/S0140-6736(06)68653-4
89. Checkley, W., White, A. C., Jaganath, D., Arrowood, M. J., Chalmers, R. M., Chen, X. M., & Guerrant, R. L. (2015). A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. The Lancet Infectious Diseases, 15(1), 85–94. https://doi.org/10.1016/S1473-3099(14)70772-8
90. Kennedy, P. G. E. (2013). Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). The Lancet Neurology, 12(2), 186–194. https://doi.org/10.1016/S1474-4422(12)70296-X
91. Morens, D. M., & Fauci, A. S. (2020). Emerging pandemic diseases: How we got to COVID-19. Cell, 182(5), 1077–1092. https://doi.org/10.1016/j.cell.2020.08.021
92. Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., & Hay, S. I. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504–507. https://doi.org/10.1038/nature12060
93. Torgerson, P. R., & Macpherson, C. N. L. (2011). The socioeconomic burden of parasitic zoonoses: Global trends. Veterinary Parasitology, 182(1), 79–95. https://doi.org/10.1016/j.vetpar.2011.07.017
94. Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., & Dondorp, A. M. (2014). Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of

Medicine, 371(5), 411–423. https://doi.org/10.1056/NE

95. Van Boeckel, T. P., Brower, C., Gilbert, M., Grenfell, B. T., Levin, S. A., Robinson, T. P., & Laxminarayan, R. (2015). Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences, 112(18), 5649–5654. https://doi.org/10.1073/pnas.1503141112
96. Reddy, A. S., & Zhang, S. (2013). Polypharmacology: Drug discovery for the future. Expert Review of Clinical Pharmacology, 6(1), 41–47. https://doi.org/10.1586/ecp.12.74
97. Zinsstag, J., Schelling, E., Waltner-Toews, D., & Tanner, M. (2011). From "one medicine" to "one health" and systemic approaches to health and well-being. Preventive Veterinary Medicine, 101(3–4), 148–156. https://doi.org/10.1016/j.prevetmed.2010.07.003
98. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
99. Karesh, W. B., Dobson, A., Lloyd-Smith, J. O., Lubroth, J., Dixon, M. A., Bennett, M., &Heymann, D. L. (2012). Ecology of zoonoses: Natural and unnatural histories. The Lancet, 380(9857), 1936–1945. https://doi.org/10.1016/S0140-6736(12)61678-X
100. Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future: Big data, machine learning, and clinical medicine. New England Journal of Medicine, 375(13), 1216–1219. https://doi.org/10.1056/NEJMp1606181
101. Woolhouse, M., Ward, M., van Bunnik, B., & Farrar, J. (2015). Antimicrobial resistance in humans, livestock and the wider environment. Philosophical Transactions of the Royal Society B: Biological Sciences, 370(1670), 20140083. https://doi.org/10.1098/rstb.2014.0083
102. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702. https://doi.org/10.1016/j.cell.2020.01.021
103. Prüss-Ustün, A., Wolf, J., Corvalán, C., Neville, T., Bos, R., & Neira, M. (2016). Diseases due to unhealthy environments: An updated estimate of the global burden of disease attributable to environmental risk factors. Journal of Public Health, 39(3), 464–475. https://doi.org/10.1093/pubmed/fdw085
104. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
105. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., & Cars, O. (2013). Antibiotic resistance: The need for global solutions. The Lancet Infectious Diseases, 13(12), 1057–1098. https://doi.org/10.1016/S1473-3099(13)70318-9
106. Tyers, M., & Wright, G. D. (2019). Drug combinations: A strategy to extend the life of antibiotics in the 21st century. Nature Reviews Microbiology, 17(3), 141–155. https://doi.org/10.1038/s41579-018-0141-x
107. Benelli, G. (2016). Plant-mediated biosynthesis of nanoparticles as an emerging tool against mosquitoes of medical and veterinary importance: A review. Parasitology Research, 115(1), 23–34. https://doi.org/10.1007/s00436-015-4800-9
108. Tilman, D., Clark, M., Williams, D. R., Kimmel, K., Polasky, S., & Packer, C. (2017). Future threats to biodiversity and pathways to their prevention. Nature, 546(7656), 73–81. https://doi.org/10.1038/nature22900
109. Tagliabue, A., & Rappuoli, R. (2023). Changing priorities in vaccinology and antimicrobial therapy in the post-pandemic era. Frontiers in Immunology, 14, 1162901.

110. Breijyeh, Z., & Karaman, R. (2022). Comprehensive review on antimicrobial resistance: Mechanisms, current therapeutic strategies, and future directions. Molecules, 27(3), 1–28.
111. Naghavi, M., et al. (2024). Global burden of antimicrobial resistance: Updated estimates from the Global Antimicrobial Resistance Research and Development Hub. Nature Medicine, 30(1), 45–60.
112. Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2022). Antibiotics: Past, present and future. Current Opinion in Microbiology, 51, 72–80.
113. Miethke, M., et al. (2021). Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 5(10), 726–749.
114. Gajdács, M., et al. (2023). Phytochemicals as potential antimicrobial agents: Current evidence and future perspectives. Antibiotics, 12(4), 672.
115. Dagar, V. K., et al. (2022). Nanotechnology-based drug delivery systems for infectious diseases: Recent advances and challenges. Journal of Controlled Release, 348, 58–82.
116. Romo, J. A., & Bhatt, T. (2023). Advances in nanotechnology for the treatment and diagnosis of infectious diseases. Frontiers in Nanotechnology, 5, 1123989.
117. Pushpakom, S., et al. (2022). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58.
118. Chen, Y., et al. (2023). Computational approaches for the discovery of novel antimicrobial agents: A comprehensive review. Briefings in Bioinformatics, 24(1), bbac552.
119. Cheng, F., et al. (2023). In silico approaches to drug discovery against antimicrobial-resistant pathogens. Drug Discovery Today, 28(3), 103489.
120. de Martel, C., et al. (2020). Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer, 141(4), 664–670.

Access this Article in Online

Website: www.ijarbs.com

Subject: Medical Microbiology

Quick Response Code

DOI:10.22192/ijarbs.2026.13.07.003

How to cite this article:
Venkatajothi Ramarao, Seethalakshmi Illanchezian. (2026). Innovations in Medical Microbiology and Therapeutic Development: A Comprehensive Review. Int. J. Adv. Res. Biol. Sci. 13(7): 24-44.
DOI: http://dx.doi.org/10.22192/ijarbs.2026.13.07.003